Eli Lilly unveils long-term data on Omvoh for Crohn's disease

Eli Lilly (NYSE: LLY) reported long-term VIVID program results showing durable Crohn's disease control with Omvoh (mirikizumab-mrkz): among patients who achieved outcomes at Year 1, clinical remission 92.4%, corticosteroid-free remission 91.2% at Week 152, and sustained bowel urgency improvements.

Post hoc analyses showed nearly 50% fewer Crohn's-related hospitalizations/surgeries weeks 0–12 and nearly 70% fewer during weeks 12–52 versus placebo; Omvoh is approved in 47 countries.

https://www.stocktitan.net/news/LLY/patients-with-crohn-s-disease-maintained-steroid-free-remission-for-et7p8fe6hzwy.html